Equities Analysts Set Expectations for ALLO Q1 Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Equities research analysts at William Blair issued their Q1 2026 earnings per share estimates for Allogene Therapeutics in a research report issued on Friday, March 14th. William Blair analyst S. Corwin anticipates that the company will earn ($0.29) per share for the quarter. The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.28) per share. William Blair also issued estimates for Allogene Therapeutics’ Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.30) EPS and Q4 2026 earnings at ($0.30) EPS.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06.

ALLO has been the topic of a number of other reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 price target on shares of Allogene Therapeutics in a report on Friday, March 14th. Citizens Jmp upgraded Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective for the company in a research report on Friday, March 14th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price objective on shares of Allogene Therapeutics in a research report on Friday, March 14th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $9.40.

Allogene Therapeutics Price Performance

Shares of NASDAQ:ALLO opened at $1.69 on Monday. The company has a market cap of $354.35 million, a P/E ratio of -1.08 and a beta of 1.02. Allogene Therapeutics has a 1 year low of $1.32 and a 1 year high of $4.63. The stock’s fifty day moving average price is $1.92 and its 200-day moving average price is $2.30.

Insiders Place Their Bets

In other Allogene Therapeutics news, CEO David D. Chang sold 46,668 shares of the company’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $1.96, for a total value of $91,469.28. Following the completion of the sale, the chief executive officer now owns 5,276,569 shares in the company, valued at $10,342,075.24. This represents a 0.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Zachary Roberts sold 27,199 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total value of $48,414.22. Following the completion of the sale, the executive vice president now owns 488,054 shares of the company’s stock, valued at approximately $868,736.12. The trade was a 5.28 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 104,866 shares of company stock worth $194,461 over the last quarter. 24.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Allogene Therapeutics

Institutional investors have recently made changes to their positions in the business. Cibc World Markets Corp purchased a new stake in shares of Allogene Therapeutics during the fourth quarter worth about $26,000. PAX Financial Group LLC purchased a new stake in shares of Allogene Therapeutics during the fourth quarter worth about $27,000. RPO LLC purchased a new stake in shares of Allogene Therapeutics during the fourth quarter worth about $31,000. Caption Management LLC purchased a new stake in shares of Allogene Therapeutics during the fourth quarter worth about $32,000. Finally, Syon Capital LLC purchased a new stake in shares of Allogene Therapeutics during the fourth quarter worth about $39,000. Hedge funds and other institutional investors own 83.63% of the company’s stock.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).